197 related articles for article (PubMed ID: 38687921)
21. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
22. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.
Jalili-Nik M; Soltani A; Mashkani B; Rafatpanah H; Hashemy SI
Int Immunopharmacol; 2021 Sep; 98():107870. PubMed ID: 34153661
[TBL] [Abstract][Full Text] [Related]
23. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
[TBL] [Abstract][Full Text] [Related]
24. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Hudson K; Cross N; Jordan-Mahy N; Leyland R
Front Immunol; 2020; 11():568931. PubMed ID: 33193345
[TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.
Fan J; Shen X; Wang Y; Zhou HL; Liu G; Li YL; Xu ZX
Biomed Pharmacother; 2020 Oct; 130():110621. PubMed ID: 34321165
[TBL] [Abstract][Full Text] [Related]
27. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
28. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
31. [Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors].
Huang HF; Zhu H; Yang XT; Guo XY; Li SS; Xie Q; Tian XB; Yang Z
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):410-414. PubMed ID: 31216825
[TBL] [Abstract][Full Text] [Related]
32. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
[TBL] [Abstract][Full Text] [Related]
37. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
38. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
39. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.
Wu Q; Jiang L; Li SC; He QJ; Yang B; Cao J
Acta Pharmacol Sin; 2021 Jan; 42(1):1-9. PubMed ID: 32152439
[TBL] [Abstract][Full Text] [Related]
40. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]